News

July 23, 2020July 23, 2020

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

News

Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers in Europe. The CE mark is ... Read more

July 20, 2020July 20, 2020

EU Certifies Software That Assesses Short-term Breast Cancer Risk

News

ProFound AI Risk, a diagnostic tool that estimates the risk of breast cancer over a two-year period following a mammogram, has received a CE mark from the European Commission. The CE mark ... Read more

July 16, 2020July 16, 2020

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

News

Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease ... Read more

July 13, 2020July 13, 2020

Diet Rich in Fiber Linked to Lower Breast Cancer Risk, Pooled Data Show

News

A diet high in total fiber appears to lower the risk of breast cancer for both pre- and postmenopausal women, researchers who pooled data from 20 observational studies reported. This association was ... Read more

July 9, 2020July 9, 2020

EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer

News

The European Medicines Agency (EMA) has validated Daiichi Sanyoko‘s marketing authorization application for trastuzumab deruxtecan (DS-8201) for the treatment of inoperable or metastatic HER2-positive breast cancer, the company announced. The ... Read more

July 6, 2020July 6, 2020

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

News

When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 trial ... Read more

July 1, 2020July 1, 2020

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

News

The U.S. Food and Drug Administration (FDA) has approved Phesgo, an under-the-skin injection of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, as a faster and more convenient alternative to treat people with HER2-positive ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

June 29, 2020June 29, 2020

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

News

UbiVac and Bristol Myers Squibb have announced plans to collaborate on a clinical trial to test whether a combination therapy approach can boost cancer immunity in patients with advanced triple ... Read more

June 22, 2020June 22, 2020

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

News

Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase ... Read more